{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:27:26Z","timestamp":1792290446973,"version":"4.4.0"},"reference-count":101,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Allergy, Immunology, and Pulmonology"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Severe asthma represents a significant challenge for children and adolescents. At the same time, it often places a burden on patients, caregivers, and society, mainly related to morbidity, mortality, and health care resources. In children and adolescents, severe asthma is mostly characterized by type 2 inflammation, which leads to bronchial eosinophilia that may be suppressed by corticosteroids. However, in this age group, a high dosage of inhaled corticosteroids combined with systemic corticosteroids sometimes results in unacceptable side effects, such as reduced growth velocity and reduced bone mineral density. Therefore, there is increasing and enthusiastic interest in today's biologics, including omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab. There is growing evidence that they may be effective and safe add-on options for children and adolescents.<\/jats:p>\n                    <jats:p>In 2009, omalizumab was approved by the European Medicines Agency as the first available therapeutic option for allergic asthma in patients as young as 6 years of age, followed by a similar approval by the U.S. Food and Drug Administration in 2016. Previously, omalizumab was marketed for this indication in patients \u2265 age 12. Subsequent biologics, namely mepolizumab, reslizumab, and benralizumab, are IL-5 targeted agents that are presently approved in some countries for severe eosinophilic asthma starting at 6 years of age. Dupilumab is targeted against the IL-4 receptor \u03b1-chain, and it has been approved in the United States and the European Union as an add-on maintenance therapy in patients \u226512 years of age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This review presents the most recent evidence on approved biologics for the treatment of severe asthma and discusses the unmet needs and future perspective, focusing on the pediatric and adolescent age groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/ped.2020.1212","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T10:31:55Z","timestamp":1605263515000},"page":"168-176","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Biologics to Treat Severe Asthma in Children and Adolescents: A Practical Update"],"prefix":"10.1177","volume":"33","author":[{"given":"Gian Luigi","family":"Marseglia","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelia","family":"Licari","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Angela","family":"Tosca","sequence":"additional","affiliation":[{"name":"Pediatric Allergy Center, Istituto Giannina Gaslini, Genoa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Ciprandi","sequence":"additional","affiliation":[{"name":"Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,12,16]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.04.031"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33311-1"},{"key":"e_1_3_4_5_2","article-title":"Advancing the care of severe asthma: differential diagnosis, multidisciplinary management, and patient engagement","author":"Corren J","year":"2020","unstructured":"Corren J, , Yawn BP. Advancing the care of severe asthma: differential diagnosis, multidisciplinary management, and patient engagement. Am J Med, 2020 [Epub ahead of print]; DOI: 10.1016\/j.amjmed.2019.02.002.","journal-title":"Am J Med"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1313117"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.11.008"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/bs9070078"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00170"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-017-0688-z"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2018.00186"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2015.10.008"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00780-2015"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-016-0217-z"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/ped.2018.0886"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/cea.12880"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000342"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/bs.vh.2016.10.010"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.10.034"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1159\/000336418"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2018.1396315"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1439463"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2015.1086645"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1517\/17460441.2015.1048220"},{"key":"e_1_3_4_25_2","unstructured":"Xolair. FDA Highlights of prescribing information. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/103976s5225lbl.pdf Accessed July18 2020."},{"key":"e_1_3_4_26_2","unstructured":"Xolair. EMA Summary of Product Characteristics. Available at: www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-xolair-25-june-2009_en.pdf Accessed July18 2020."},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-014-0107-z"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.03.002"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2011-301570"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009705"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.09.021"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.09.008"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12405"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00149812"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00008115"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.2174\/1573398X13666170426094536"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.23845"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62175-8"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2010.539502"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.01.033"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.02.007"},{"key":"e_1_3_4_42_2","first-page":"CD003559","article-title":"Omalizumab for asthma in adults and children","volume":"1","author":"Normansell R","year":"2014","unstructured":"Normansell R, , Walker S, , Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev, 2014; 1:CD003559.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.12.045"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13373"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/pai.12813"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2018.39.4146"},{"key":"e_1_3_4_47_2","unstructured":"Preventing Asthma in High Risk Kids (PARK). ClinicalTrials.gov Identifier: NCT02570984. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02570984 Accessed July18 2020."},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02144.x"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2014.02.003"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210017"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.08.054"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.13678"},{"key":"e_1_3_4_53_2","unstructured":"Nucala prescribing information. Available at: www.gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Nucala\/pdf\/NUCALA-PI-PIL-IFU-COMBINED.PDF Accessed July18 2020."},{"key":"e_1_3_4_54_2","unstructured":"Nucala EMA product information. Available at: www.ema.europa.eu\/en\/documents\/product-information\/nucala-epar-product-information_en.pdf Accessed July18 2020."},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200701-085OC"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-018-0689-2"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"e_1_3_4_58_2","first-page":"81","article-title":"Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma","volume":"11","author":"Haldar P","year":"2017","unstructured":"Haldar P. Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma. Biologics, 2017; 11:81\u201395.","journal-title":"Biologics"},{"key":"e_1_3_4_59_2","unstructured":"Mepolizumab for treating severe refractory eosinophilic asthma_NICE. Available at: www.nice.org.uk\/guidance\/ta431 Accessed September24 2020."},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2013.11.026"},{"key":"e_1_3_4_61_2","first-page":"CD010834","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne HA","year":"2017","unstructured":"Farne HA, , Wilson A, , Powell C, et al. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev, 2017; 9:CD010834.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2016.07.010"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.09.033"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1080\/20018525.2018.1536097"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.12.034"},{"key":"e_1_3_4_68_2","first-page":"52","article-title":"Mepolizumab for severe eosinophilic asthma: a comparison of efficacy in children, adolescents, and adults. Poster No: PA5447. ERS 2018","author":"Gupta A","year":"2018","unstructured":"Gupta A, , Steinfeld J, , Price RG, et al. Mepolizumab for severe eosinophilic asthma: a comparison of efficacy in children, adolescents, and adults. Poster No: PA5447. ERS 2018. Eur Respir J, 2018; 52.","journal-title":"Eur Respir J"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.08.005"},{"key":"e_1_3_4_70_2","unstructured":"Logan JK Harinstein L Mu\u00f1oz M. Pediatric Postmarketing Pharmacovigilance Review: Cinqair (Reslizumab). Available at: www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/PediatricAdvisoryCommittee\/UCM610723.pdf Accessed July18 2020."},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.018"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.03.032"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(15)00042-9"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2017.01.011"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.12.997"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.08.024"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201707-1323OC"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201708-1668OC"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-018-0968-8"},{"key":"e_1_3_4_80_2","unstructured":"Fasenra. FDA highlights of prescribing information. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761070s000lbl.pdf Accessed July18 2020."},{"key":"e_1_3_4_81_2","unstructured":"AstraZeneca. Fasenra (benralizumb). Summary of product characteristics. 2018. Available at: http:\/\/ec.europa.eu\/health\/documents\/communityregister\/2018\/20180108139598\/anx_139598_en.pdf Accessed July18 2020."},{"key":"e_1_3_4_82_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2017.1359253"},{"key":"e_1_3_4_83_2","first-page":"5698212","article-title":"Anti-IL-5 and IL-5Ra: efficacy and safety of new therapeutic strategies in severe uncontrolled asthma","author":"Bagnasco D","year":"2018","unstructured":"Bagnasco D, , Caminati M, , Ferrando M, et al. Anti-IL-5 and IL-5Ra: efficacy and safety of new therapeutic strategies in severe uncontrolled asthma. Biomed Res Int, 2018: 5698212.","journal-title":"Biomed Res Int"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00936-2018"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"e_1_3_4_86_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703501"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1371"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30190-X"},{"key":"e_1_3_4_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(18)30406-5"},{"key":"e_1_3_4_91_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2017.1282458"},{"key":"e_1_3_4_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30307-5"},{"key":"e_1_3_4_93_2","unstructured":"Dupixent. EMA Summary of Product Characteristics. Available at: www.ema.europa.eu\/en\/documents\/product-information\/dupixent-epar-product-information_en.pdf Accessed July18 2020."},{"key":"e_1_3_4_94_2","unstructured":"Dupixent. FDA highlights of prescribing information. Available at: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761055s007lbl.pdf Accessed July18 2020."},{"key":"e_1_3_4_95_2","unstructured":"Sanofi Evaluation of dupilumab in patients with persistent asthma (Liberty asthma quest). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02414854. NLM identifier: NCT02414854. Accessed September20 2020."},{"key":"e_1_3_4_96_2","unstructured":"Sanofi Evaluation of dupilumab in patients with severe steroid-dependent asthma (VENTURE). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02528214. NLM identifier: NCT02528214. Accessed September20 2020."},{"key":"e_1_3_4_97_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"e_1_3_4_98_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-020-00387-2"},{"key":"e_1_3_4_99_2","unstructured":"Sanofi Evaluation of dupilumab in children with uncontrolled asthma (VOYAGE). Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02948959. NLM identifier: NCT02948959. Accessed September20 2020."},{"key":"e_1_3_4_100_2","doi-asserted-by":"publisher","DOI":"10.1002\/ppul.24613"},{"key":"e_1_3_4_101_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14221"},{"key":"e_1_3_4_102_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.14235"}],"container-title":["Pediatric Allergy, Immunology, and Pulmonology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/ped.2020.1212","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/ped.2020.1212","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/ped.2020.1212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:14:53Z","timestamp":1777677293000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/ped.2020.1212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1089\/ped.2020.1212"],"URL":"https:\/\/doi.org\/10.1089\/ped.2020.1212","relation":{},"ISSN":["2151-321X","2151-3228"],"issn-type":[{"value":"2151-321X","type":"print"},{"value":"2151-3228","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}